Premium
Antitumor activity of paclitaxel against human breast carcinoma xenografts serially transplanted into nude mice
Author(s) -
Kubota Tetsuro,
Matsuzaki Shinjiro Wilson,
Hoshiya Yasunori,
Watanabe Masahiko,
Kitajima Masaki,
Asanuma Fumiki,
Yamada Yoshinori,
Koh JunIchi
Publication year - 1997
Publication title -
journal of surgical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.201
H-Index - 111
eISSN - 1096-9098
pISSN - 0022-4790
DOI - 10.1002/(sici)1096-9098(199702)64:2<115::aid-jso5>3.0.co;2-e
Subject(s) - paclitaxel , medicine , nude mouse , pharmacology , chemotherapy , in vitro , pharmacokinetics , carcinoma , breast cancer , mtt assay , breast carcinoma , in vivo , cancer , cancer research , biology , biochemistry , microbiology and biotechnology
Background Paclitaxel (BMS‐181339: Taxol) is a promising agent against previously treated breast cancer. The antitumor activity of paclitaxel was evaluated using five human breast carcinoma xenografts in nude mice. Methods Paclitaxel at 20 mg/kg dissolved in 0.2 ml ethanol/cremophor EL solution was administered intraperitoneally daily for 5 days. Results Paclitaxel showed significant antitumor activity against MCF‐7 and MX‐1, but only limited activity against the other three xenografts (R‐27, Br‐10, and T‐61), suggesting its substantially different antitumor spectrum from conventional antibreast cancer drugs. The different sensitivity of xenografts to paclitaxel was successfully reproduced in vitro using the MTT assay, when the cutoff concentration of paclitaxel was 20 μg/ml. Conclusion Since no significant differences were observed in the pharmacokinetics of paclitaxel in sensitive and resistant tumor cell lines, the efficacy of this agent seemed to depend on the sensitivity of tumor cells rather than the intratumoral concentration of agent. J. Surg. Oncol. 64: 115–121. © 1997 Wiley‐Liss, Inc.